CAJ | 학술논문

目的观察多西他赛(国产艾素)单药联合放疗与顺铂(DDP)加5-氟尿嘧啶(5-FU)联合放疗治疗局部晚期鼻咽癌的比较.方法 47例局部晚期鼻咽癌患者随机分为治疗组24例,对照组23例,治疗组单药多西他赛35mg/m2,1次/周,同期直线加速器放疗;对照组顺铂30mg/m2,第1～3天,5-氟尿嘧啶500mg/m2,第1～5天,同期直线加速器放疗.结果近期疗效评价,鼻咽原发灶及颈部淋巴结(CR+PR),两组差异无统计学意义(P>0.05);1年内两组无疾病进展生存率(PFS)差异无统计学意义(P>0.05);两组不良反应比较,治疗组恶心、呕吐及口腔粘膜反应明显低于对照组(P<0.05),但中性粒细胞减少发生率高于对照组(P<0.05).结论单药多西他赛治疗鼻咽癌,近期疗效相似,不良反应轻微,可耐受,是局部晚期鼻咽癌可选择的药物.
목적 관찰다서타새(국산애소)단약연합방료여순박(DDP)가5-불뇨밀정(5-FU)연합방료치료국부만기비인암적비교.방법 47례국부만기비인암환자수궤분위치료조24례,대조조23례,치료조단약다서타새35mg/m2,1차/주,동기직선가속기방료;대조조순박30mg/m2,제1～3천,5-불뇨밀정500mg/m2,제1～5천,동기직선가속기방료.결과 근기료효평개,비인원발조급경부림파결(CR+PR),량조차이무통계학의의(P>0.05);1년내량조무질병진전생존솔(PFS)차이무통계학의의(P>0.05);량조불량반응비교,치료조악심、구토급구강점막반응명현저우대조조(P<0.05),단중성립세포감소발생솔고우대조조(P<0.05).결론 단약다서타새치료비인암,근기료효상사,불량반응경미,가내수,시국부만기비인암가선택적약물.
Objective To evaluate the objective anti-tumor efficacy of decetaxel combined with radiotherapy versus cispla-tin/5-fluorouracil(CF) regimen combined with radiotherapy on locally advanced nasopharyngeal carcinoma. Methods 47 cases of locally advanced nasopharyngeal carcinoma were randomized into docetaxel group (n=24) and CF group (n=23), patients in do-cetaxel group received docetaxel 35mg/m2 iv once a week during 7 or 8 weeks and received radiotherapy by linear accelerator simul-taneously while patients in CF group received cisplatin 30mg/m2 iv dl-3, 5-Fu 500 mg/m2 iv dl～5 at the 1st and 5th week and the radiotherapy was performed as the docetaxel group. Results The change of primary cancer and metastasis of neck lymph nodes were no significant difference between two groups. There was also no significant difference in 1 year disease progress-free survival rate between two groups. The occurrence rates of nausea,vomiting and mucositis in docetaxel group was less than in CF group, while the occurrence rate of leucopenia was higher than in CF group. Conclusion There is no difference in effects on local ad-vanced nasopharyngeal carcinoma between docetaxel and PF regimen, and 1 year disease progress-free survival rates of them are compared, while the former have a better tolerance to be a suitable treatment for local advanced nasopharyngeal carcinoma.